Total Payments
$141,091
2024 Payments
$48,418
Companies
26
Transactions
242
Medicare Patients
1,431
Medicare Billing
$410,761
Payment Breakdown by Category
Consulting$81,964 (58.1%)
Other$38,469 (27.3%)
Travel$9,406 (6.7%)
Food & Beverage$8,028 (5.7%)
Research$2,820 (2.0%)
Education$404.95 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $81,964 | 27 | 58.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,793 | 32 | 22.5% |
| Travel and Lodging | $9,406 | 46 | 6.7% |
| Food and Beverage | $8,028 | 111 | 5.7% |
| Honoraria | $6,676 | 6 | 4.7% |
| Unspecified | $2,820 | 14 | 2.0% |
| Education | $404.95 | 6 | 0.3% |
Payments by Type
General
$138,272
228 transactions
Research
$2,820
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Veloxis Pharmaceuticals, Inc. | $27,050 | 42 | $0 (2024) |
| GlaxoSmithKline, LLC. | $26,144 | 24 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $20,281 | 33 | $0 (2024) |
| Travere Therapeutics, Inc. | $17,299 | 33 | $0 (2024) |
| Lilly USA, LLC | $8,430 | 8 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,098 | 10 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,486 | 10 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $6,606 | 5 | $0 (2023) |
| AbbVie, Inc. | $3,614 | 13 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $3,445 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,418 | 73 | Travere Therapeutics, Inc. ($15,443) |
| 2023 | $27,631 | 46 | GlaxoSmithKline, LLC. ($12,003) |
| 2022 | $36,995 | 50 | GlaxoSmithKline, LLC. ($13,197) |
| 2021 | $12,947 | 18 | Veloxis Pharmaceuticals, Inc. ($6,585) |
| 2020 | $7,444 | 15 | Veloxis Pharmaceuticals, Inc. ($5,624) |
| 2019 | $1,503 | 18 | GlaxoSmithKline, LLC. ($943.62) |
| 2018 | $1,790 | 6 | Mallinckrodt LLC ($1,555) |
| 2017 | $4,363 | 16 | AbbVie, Inc. ($3,543) |
All Payment Transactions
242 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/12/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $137.44 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $648.38 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $128.62 | General |
| 11/06/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $34.19 | General |
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Cardio-renal | ||||||
| 10/26/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $81.65 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/26/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $71.50 | General |
| 10/25/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,751.09 | Research |
| Study: Research Publication/ Writing Support | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $49.84 | General |
| 10/24/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $126.86 | General |
| Category: Immunology | ||||||
| 10/24/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $57.29 | General |
| Category: Nephrology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $39.61 | General |
| 10/24/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $26.31 | General |
| 10/23/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $56.38 | General |
| Category: NEPHROLOGY | ||||||
| 10/14/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 10/14/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $135.94 | General |
| 10/14/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $32.44 | General |
| 10/09/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $70.94 | General |
| Category: Nephrology | ||||||
| 10/01/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: NEPHROLOGY | ||||||
| 09/27/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Nephrology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 09/27/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $402.58 | General |
| 09/27/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $339.29 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $1,751 | 1 |
| A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | GlaxoSmithKline, LLC. | $943.62 | 12 |
| TWO PART PROSPECTIVE STUDY OF H.P. ACTHAR GEL IN THE TREATMENT OF PROTEINURIA DUE TO IDIOPATHIS FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Mallinckrodt LLC | $125.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 307 | 654 | $252,115 | $74,025 |
| 2022 | 6 | 297 | 675 | $274,186 | $82,429 |
| 2021 | 6 | 397 | 926 | $402,579 | $122,137 |
| 2020 | 8 | 430 | 1,055 | $522,722 | $132,171 |
Total Patients
1,431
Total Services
3,310
Medicare Billing
$410,761
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Facility | 2023 | 17 | 152 | $144,400 | $40,003 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 292 | $61,028 | $19,129 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 49 | 49 | $19,551 | $6,215 | 31.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 78 | $10,842 | $4,475 | 41.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 28 | 50 | $12,100 | $2,651 | 21.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 14 | $3,738 | $1,393 | 37.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 12 | 19 | $456.00 | $159.60 | 35.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Facility | 2022 | 21 | 166 | $157,700 | $45,756 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 160 | 317 | $66,253 | $20,989 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 74 | $14,874 | $5,645 | 38.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 42 | 74 | $17,908 | $4,078 | 22.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 29 | 29 | $11,571 | $3,539 | 30.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 15 | $5,880 | $2,421 | 41.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 37 | 236 | $224,200 | $64,736 | 28.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 163 | 311 | $64,999 | $21,281 | 32.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 63 | 149 | $29,949 | $12,435 | 41.5% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 68 | 154 | $37,268 | $8,650 | 23.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Facility | 2021 | 19 | 29 | $27,550 | $8,153 | 29.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $10,773 | $3,626 | 33.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $7,840 | $3,254 | 41.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 37 | 236 | $224,200 | $52,856 | 23.6% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Facility | 2020 | 26 | 158 | $150,100 | $34,560 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 164 | 308 | $64,372 | $17,084 | 26.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 49 | 115 | $23,115 | $9,932 | 43.0% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 65 | 141 | $34,122 | $8,205 | 24.0% |
About Dr. Mohanram Narayanan, M.D
Dr. Mohanram Narayanan, M.D is a Nephrology healthcare provider based in Temple, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962462341.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohanram Narayanan, M.D has received a total of $141,091 in payments from pharmaceutical and medical device companies, with $48,418 received in 2024. These payments were reported across 242 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($81,964).
As a Medicare-enrolled provider, Narayanan has provided services to 1,431 Medicare beneficiaries, totaling 3,310 services with total Medicare billing of $410,761. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Temple, TX
- Active Since 03/28/2006
- Last Updated 01/07/2021
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1962462341
Products in Payments
- Envarsus (Drug) $23,541
- JARDIANCE (Drug) $15,916
- TOLVAPTAN (Drug) $7,982
- JYNARQUE (Drug) $6,646
- TARPEYO (Drug) $3,182
- ENVARSUS (Drug) $2,811
- LOKELMA (Drug) $1,994
- ACTHAR (Biological) $1,755
- Monoferric (Drug) $1,500
- FARXIGA (Drug) $1,150
- Renal - Revaclear (Device) $862.00
- LUPKYNIS (Drug) $690.42
- Envarsus XR (Drug) $500.00
- Fabhalta (Drug) $264.30
- Kerendia (Drug) $245.54
- Veltassa (Drug) $228.05
- BENLYSTA (Biological) $186.99
- Soliris (Drug) $150.00
- RAYALDEE (Drug) $128.71
- SOLIRIS (Drug) $125.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Temple
Tony Issac, Md, MD
Nephrology — Payments: $1,169
Nephrology $1,169
Abraham Rajan, Md, MD
Nephrology — Payments: $937.48
Nephrology $937.48
Dr. Nimrit Goraya, M.d, M.D
Nephrology — Payments: $920.22
Nephrology $920.22
Dr. Nidhi Mattoo Munshi
Nephrology — Payments: $772.52
Nephrology $772.52
Dr. Luciana Mclean, M.d, M.D
Nephrology — Payments: $736.78
Nephrology $736.78
Dr. Luis Concepcion, M.d, M.D
Nephrology — Payments: $539.19
Nephrology $539.19